Eljamel MS et al., 2007-10-10: Single-centre randomised trial in glioblastoma (27 patients) using ALA and Photofrin fluorescence-guided resection plus repeated PDT: mean survival 52.8 versus 24.6 weeks – the clinical brain-tumour PDT record, and it belongs to porphyrins, not methylene blue.
The mean survival of the study group was 52.8 weeks compared to 24.6 weeks in the control group (p<0.01).
Eljamel MS et al., 2007-10-10: Single-centre randomised trial in glioblastoma (27 patients) using ALA and Photofrin fluorescence-guided resection plus repeated PDT: mean survival 52.8 versus 24.6 weeks – the clinical brain-tumour PDT record, and it belongs to porphyrins, not methylene blue. C8 Eljamel 2008. Study type: single-centre randomised controlled trial, N=27 (13 study, 14 control). Country: UK (Ninewells Hospital, Dundee). Agents: 5-aminolevulinic acid and porfimer sodium (Photofrin) – NOT methylene blue. Dose/light dose: not stated in the abstract. Funder/conflicts: not stated in the record. Comparator: conventional resection without PDT. Bearing is CONTRADICTS for the source's claim that the clinical PDT record for glioblastoma is methylene blue's; the trial is real and positive but uses other photosensitizers. Note the authors themselves call for a multicentre trial to confirm. Study type: randomized trial.
